CDK4/6 inhibitors as adjuvant treatment for hormone receptor-positive, HER2-negative early breast cancer: a systematic review and meta-analysis

BACKGROUND: The combination of cyclin-dependent kinases 4/6 inhibitors (CDK4/6is) and endocrine therapy (ET) is standard of care for patients with hormone receptor-positive (HR+), HER2-negative (HER2−) advanced breast cancer (BC). However, studies evaluating adjuvant CDK4/6is provided contradictory...

Descripción completa

Detalles Bibliográficos
Autores principales: Agostinetto, E., Vian, L., Caparica, R., Bruzzone, M., Ceppi, M., Lambertini, M., Pondé, N., de Azambuja, E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8010395/
https://www.ncbi.nlm.nih.gov/pubmed/33743330
http://dx.doi.org/10.1016/j.esmoop.2021.100091

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8010395/
https://www.ncbi.nlm.nih.gov/pubmed/33743330
http://dx.doi.org/10.1016/j.esmoop.2021.100091

Ejemplares similares